Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus Long-Term Follow-Up for Angiomyolipoma in TSC and LAM
NCT00792766Phase 2Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Dec 2008
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in angiomyolipoma (AML), tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: RAD001 tolerance. Started Dec 2008; status: completed.
02
Drugs
everolimus
03
Conditions
angiomyolipoma (AML)tuberous sclerosis complex (TSC)lymphangioleiomyomatosis (LAM)
Beyond the preview
Go deeper on NCT00792766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00792766.